FY2026 EPS Estimates for Prothena Boosted by HC Wainwright

Prothena Corporation plc (NASDAQ:PRTA) – Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Prothena in a report released on Friday, February 20th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $1.81 per share for the year, up from their previous estimate of $1.80. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at $1.14 EPS.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, February 19th. The biotechnology company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.67 million. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.

A number of other analysts have also recently issued reports on the company. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group set a $36.00 price target on shares of Prothena in a report on Tuesday, October 28th. Royal Bank Of Canada increased their price objective on shares of Prothena from $11.00 to $12.00 and gave the company a “sector perform” rating in a research note on Friday. Citigroup reiterated a “market outperform” rating on shares of Prothena in a research report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Prothena in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Prothena presently has an average rating of “Hold” and a consensus price target of $22.00.

Prothena Price Performance

NASDAQ:PRTA opened at $9.02 on Monday. Prothena has a one year low of $4.32 and a one year high of $16.67. The stock has a market cap of $485.55 million, a P/E ratio of -1.99, a PEG ratio of 1.89 and a beta of -0.11. The company has a fifty day moving average price of $9.26 and a 200 day moving average price of $9.42.

Hedge Funds Weigh In On Prothena

Several institutional investors and hedge funds have recently made changes to their positions in the business. Prospera Financial Services Inc bought a new stake in shares of Prothena during the 2nd quarter valued at $61,000. CWM LLC increased its holdings in Prothena by 650.1% during the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 8,880 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Prothena during the 4th quarter valued at about $100,000. Inscription Capital LLC purchased a new stake in Prothena in the 3rd quarter worth $102,000. Finally, PDT Partners LLC purchased a new stake in Prothena in the 4th quarter worth $108,000. Institutional investors own 97.08% of the company’s stock.

Key Prothena News

Here are the key news stories impacting Prothena this week:

• Positive Sentiment: Q4 EPS slightly beat consensus (GAAP loss per share modestly narrower than expected), showing improvement versus a year ago — a near‑term positive signal for financial trajectory. Prothena Press Release (Q4 & FY2025)
• Positive Sentiment: Analyst support: RBC raised its price target from $11 to $12 (sector perform), implying meaningful upside from current levels — this can provide some analyst‑driven buying interest. Benzinga
• Neutral Sentiment: Management highlighted upcoming partner milestones and program catalysts for 2026; these are potential positive binary events but timing/outcomes remain uncertain. Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
• Neutral Sentiment: Full earnings call transcript and highlights are available for investors to parse program updates and management tone — useful for judging near‑term execution risk. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Revenue missed materially ($0.02M reported vs. ~$0.67M expected), underscoring current lack of commercial receipts and heightening sensitivity to financing and partnership milestones. Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Company provided 2026 cash‑burn guidance (planned spend and runway), which may pressure shares if investors see a need for near‑term equity financing or dilution. Business Wire — Q4 & FY2025 Results and Guidance

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.